Phase I proof-of-concept study of treprostinil, using TransCon technology for self-injection, as a potential therapy for pulmonary arterial hypertension.
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2015
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Ascendis Pharma
- 28 Apr 2015 Status changed from recruiting to completed, as reported in an Ascendis Pharma media release.
- 28 Apr 2015 Results published in an Ascendis Pharma media release.
- 14 Jan 2015 According to a media release, Ascendis Pharma expects to report results from this study in mid-2015.